SCHEMBL24323644

SCHEMBL24323644

O=C(NC[C@H]1CCCN1)C(=O)NC1CCCCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 7/20 0.53
RAB9A P51151 5/20 0.53
NPC1 O15118 5/20 0.53
MAPT P10636 3/20 0.53
GAA P10253 1/20 0.45
EPHX1 P07099 7/20 0.42
MAPK1 P28482 1/20 0.42
DUSP3 P51452 1/20 0.42
PTPN5 P54829 1/20 0.42
PTPN11 Q06124 1/20 0.42
HTT P42858 2/20 0.41
ALDH1A1 P00352 2/20 0.40
CYP2D6 P10635 2/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 2/20 0.40
TP53 P04637 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24323660 0.98 SMN1; SMN2 (0.50) SMN1; SMN2RAB9ANPC1MAPTGAA
SCHEMBL24322652 0.94 SMN1; SMN2 (0.42) SMN1; SMN2RAB9ANPC1MAPTGAA
SCHEMBL24323552 0.80 SMN1; SMN2 (0.51) SMN1; SMN2RAB9ANPC1MAPTGAA
SCHEMBL23201079 0.78 DRD2 (0.39) SMN1; SMN2MAPTHTTCYP2D6MEN1
SCHEMBL23201076 0.78 DRD2 (0.39) SMN1; SMN2MAPTHTTCYP2D6MEN1
SCHEMBL24322789 0.77 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1MAPTGAA
SCHEMBL24322800 0.77 SMN1; SMN2 (0.47) SMN1; SMN2RAB9ANPC1MAPTGAA
SCHEMBL24322620 0.75 SMN1; SMN2 (0.44) SMN1; SMN2RAB9ANPC1MAPTGAA
SCHEMBL3335001 0.74 CYP2D6 (0.42) SMN1; SMN2MAPTHTTCYP2D6MEN1
SCHEMBL2937827 0.74 CYP2D6 (0.42) SMN1; SMN2MAPTHTTCYP2D6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof Psomagen Inc. (US) 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220122691-A1 HtrA Inhibitors and CagA Inhibitors and Use Thereof HTRA1, GIPR, HPN SMN1; SMN2 4226/4885RAB9A 435/4885NPC1 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.